From Wikipedia, the free encyclopedia
Jump to: navigation, search
Systematic (IUPAC) name
CAS Number 83903-06-4
ATC code None
PubChem CID 51670
ChemSpider 3577726
KEGG D04794
Chemical data
Formula C21H27N5O2S
Molar mass 413.54 g/mol

Lupitidine (INN) (code name SKF-93479), or lupitidine hydrochloride (USAN), is a long-acting H2 receptor antagonist[1] developed by Smith, Kline & French and described as an antiulcerogenic that was never marketed.[2] It was shown to inhibit nocturnal gastric acid secretion[3] and, in experiments on rodents, produced diffuse neuroendocrine cell hyperplasia and an increase in multifocal glandular hyperplasia due to hypergastrinemia resulting from the pharmacological suppression of gastric acid secretion.[4]


Lupitidine synthesis:[5] also:[6]


  1. ^ Franzén, L; Ghassemifar, R; Malcherek, P (July 1991). "Experimental Mast Cell Activation Improves Connective Tissue Repair in the Perforated Rat Mesentery". Agents and Actions. 33 (3–4): 371–7. doi:10.1007/bf01986588. PMID 1683107. 
  2. ^ J. Elks (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 745–. ISBN 978-1-4757-2085-3. 
  3. ^ Dammann, H.G.; Muller, P.; Simon, B. (January 1982). "Inhibition of Nocturnal Acid Secretion by H2-Receptor-Antagonist SKF 93479". The Lancet. 319 (8265): 224. doi:10.1016/S0140-6736(82)90788-7. 
  4. ^ Betton, GR; Dormer, CS; Wells, T; Pert, P; Price, CA; Buckley, P (1 February 1988). "Gastric ECL-Cell Hyperplasia and Carcinoids in Rodents Following Chronic Administration of H2-antagonists SK&F 93479 and Oxmetidine and Omeprazole". Toxicologic Pathology. 16 (2): 288–298. doi:10.1177/019262338801600222. PMID 2903544. 
  5. ^ Lam, B. L.; Pridgen, L. N.; 1982, U.S. Patent 4,352,933
  6. ^ Laird, T., Chern. Ind. (London), 1986, 134 (synth)